KalVista Pharmaceuticals, Inc.
KALV
$11.85
$0.100.85%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -15.07% | -7.66% | -14.77% | -4.51% | 9.42% |
| Total Depreciation and Amortization | -3.45% | 13.97% | 0.88% | 1.34% | 2.28% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16,095.16% | -99.38% | 357.89% | -5.37% | -81.84% |
| Change in Net Operating Assets | -140.72% | 106.31% | 2,525.82% | 109.22% | -113.91% |
| Cash from Operations | -35.03% | -23.51% | 17.56% | 1.44% | -166.27% |
| Capital Expenditure | -3.20% | -1,070.83% | 77.78% | -414.29% | -40.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 807.29% | -135.67% | -82.49% | 31.19% | 129.47% |
| Cash from Investing | 738.85% | -139.07% | -82.50% | 30.98% | 129.45% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -30.29% | -96.73% | 19,067.12% | -90.17% | -96.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 680.11% | -97.05% | -- | -- | -- |
| Cash from Financing | 398.18% | -96.93% | 51,348.47% | -90.17% | -98.00% |
| Foreign Exchange rate Adjustments | -19.05% | 369.34% | -406.88% | 247.86% | 258.11% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 79.51% | -128.23% | 1,198.26% | 16,396.61% | -99.32% |